Alligator Bioscience

About Alligator Bioscience AB (publ) 

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company’s lead drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. 

Press release 

Søren Bregenholt, CEO of Alligator Bioscience, comments: 

“The outcome of the TO 12 warrant exercise is in line with our expectations and represents a solid result in today’s challenging market environment. It reflects continued confidence in Alligator’s strategy and in mitazalimab as a potential breakthrough therapy for metastatic pancreatic cancer. With the capital secured in this round we are well-positioned to maintain development momentum and advance our preparations for a pivotal Phase 3 trial together with a partner.” 

Website: https://alligatorbioscience.se/en/